{"id":17,"date":"2023-10-11T09:11:08","date_gmt":"2023-10-11T08:11:08","guid":{"rendered":"https:\/\/www.shs-capital.eu\/?page_id=17"},"modified":"2025-08-29T10:39:50","modified_gmt":"2025-08-29T09:39:50","slug":"investment-strategy","status":"publish","type":"page","link":"https:\/\/www.shs-capital.eu\/investment-strategy\/","title":{"rendered":"Our Investment Strategy"},"content":{"rendered":"\n\n \n
\n
<\/div>\n \"\"\n \n

Investing in Fast growing Companies<\/h1>\n

We call ourselves Growth Buyout investors, which summarizes the strategy of SHS to invest in both – buyout transactions in established companies as well as growth investments in scale-up companies in the healthcare field.<\/span><\/p>\n<\/div>

\n More about Private Equity<\/a>\n More about Growth Financing<\/a>\n <\/div> <\/div>\n <\/section>\n \n\n\n
Home<\/span><\/a><\/span><\/section>\n\n\n

Private
Equity<\/h2>\n\n\n\n

Our investment focus is on established, growing companies positioned within fast-developing verticals in the healthcare industry.<\/p>\n\n\n\n

\"\"<\/figure>
\n

As Germany\u2019s leading investor for healthcare companies, we bring not only capital, but also strategic expertise as well as synergy effects from our portfolio into a partnership.<\/p>\n\n\n\n

SHS Capital’s value proposition is further amplified by its extensive network within the healthcare realm which has grown for more than past 30 years by fostering relationships with a diverse array of professionals, from leading KOLs to seasoned industry leaders.<\/p>\n<\/div><\/div>\n\n\n

\n
\n
\n
\n

Opportunities for Private Equity<\/h2>\n<\/div>\n<\/div>\n\n
\n
\n

Succession<\/h3>
Ensuring sustainable growth.<\/div>

As an investor with experience in the sector, SHS has already successfully implemented a large number of company successions for healthcare companies.<\/p> <\/div>\n

\n

International expansion<\/h3>
Opening up new markets often goes hand in hand with high capital requirements.<\/div>

SHS has already supported many medium-sized companies with capital and expertise in order to implement their plans to expand into the USA or Asia.<\/p> <\/div>\n

\n
\n\n\n\n\t\n\t\t\n\t<\/g>\n\t\n\t\t\n\t<\/g>\n\t\n\t\t\n\t<\/g>\n\t\n\t\t\n\t<\/g>\n\t\n\t\t\n\t<\/g>\n\t\n\t\t\n\t<\/g>\n\t\n\t\t\n\t<\/g>\n<\/g>\n<\/svg>\n<\/div>\n

Minority shareholdings<\/h3>
Combining strengths: SHS is interested in minority shareholdings.<\/div>

We help owners in getting their company to the next level by adding complementary teams from our network or helping to improve internal processes, setting up direct sales teams or scaling up manufacturing.<\/p> <\/div>\n <\/section>\n<\/div>\n<\/div><\/div>\n\n\n

\n
\n

We bring into a partnership<\/h2>\n<\/div>\n\n\n\n
\n
\n 01<\/span>\n Long-term view on value-enhancing measures of company building and value creation<\/span>\n <\/div>\n
\n 02<\/span>\n Many years of expertise in the analysis and implementation of growth strategies<\/span>\n <\/div>\n
\n 03<\/span>\n Business development support through our extensive network of KOLs, industry contacts and leading scientists<\/span>\n <\/div>\n <\/section>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n\n\n

Growth
Financing<\/h2>\n\n\n\n

Our growth investments focus is on companies having started the commercialization of their cutting-edge technologies.<\/p>\n\n\n\n

\"\"<\/figure>
\n

With our investments, we help shape European champions in their respective healthcare segments or support them in their further expansion.<\/p>\n\n\n\n

In addition to capital, we essentially provide our networks and expertise in the areas of approval and reimbursement (USA\/China), development of stable organizational structures, marketing\/sales, M&A and exit.<\/p>\n<\/div><\/div>\n\n\n

\n
\n
\n
\n

Growth capital
possibilities<\/h2>\n<\/div>\n<\/div>\n\n
\n
\n

Financing rollout<\/h3>
We drive the national and European market launch of your product.<\/div>

Our portfolio companies benefit from our long-standing relationships with the leading players in the healthcare sector in Europe, such as corporates, hospitals and insurance companies.<\/p> <\/div>\n

\n

Financing FDA approval<\/h3>
Entering the attractive US market can be challenging.<\/div>


Thanks to our many years of experience, working together can prevent time-consuming loops in the approval process.<\/p> <\/div>\n

\n

Financing clinical studies<\/h3>
Clinical validation is essential for the highly competitive healthcare market.<\/div>

In addition to capital, our portfolio companies benefit from our contacts to the leading study centers and consultants in Europe.<\/p> <\/div>\n <\/section>\n<\/div>\n<\/div><\/div>\n\n\n

\n
\n

We bring into a partnership<\/h2>\n<\/div>\n\n\n\n
\n
\n 01<\/span>\n A long-standing network of leading KOLs and industry experts in the healthcare sector.<\/span>\n <\/div>\n
\n 02<\/span>\n Cooperation with health insurance companies and the leading healthcare corporates<\/span>\n <\/div>\n
\n 03<\/span>\n Expertise in sector-specific topics such as IP, regulation and reimbursement<\/span>\n <\/div>\n <\/section>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n\n\n